Thursday, 28 February 2019, Washington DC

GCR is delighted to host the inaugural GCR Live Pharmaceuticals event on Thursday, 28 February 2019



J. Mark Gidley

White & Case, Washington, DC

J. Mark Gidley chairs the White & Case global Antitrust/Competition Practice, which is the only such practice to have been named Competition Group of the Year for the past six years by Law360.  His practice focuses on mergers and acquisitions, cartel cases, class actions, and pharmaceutical antitrust cases, with an emphasis on trying antitrust cases.

Christine Siegwarth Meyer

NERA Economic Consulting, New York

Featured as one of Global Competition Review's "Women in Antitrust," Dr. Christine Meyer is considered one of the foremost testifying economists in the areas of complex commercial litigation involving intellectual property, antitrust claims, and commercial damages. In the area of intellectual property, Dr. Meyer has analyzed damages and provided expert testimony concerning issues arising from patent, trademark, and copyright infringement, the misappropriation of trade secrets, and breaches of contract. She has considerable expertise in analyzing lost profits, reasonable royalties, price erosion, commercial success, and irreparable harm.


8.45: Welcome coffee and registration

9.15: Chairs’ opening remarks

Christine Meyer, NERA Economic Consulting, New York 
J Mark Gidley, White & Case, Washington DC

9.30: Keynote address

10.15: Pricing cases: what do they mean for the future of pharma?

The scrutiny of pricing in the pharmaceuticals sector has, if anything, become fiercer in 2018. How has this enforcement by the agencies and court decisions from private litigation affected the industry and its business practices?

Questions the panel are expected to discuss include:

  • What is the effect of industry consolidation on drug pricing?
  • How are the agencies evaluating the effect of mergers on short-term and longer-term pricing?
  • How has alleged collusion in the generic drugs market affected pricing, and how will those cases affect future enforcement?
  • How effective are “pay-for-delay” settlements in today’s industry?

11.30: Coffee break

12.00: Innovation: a double-edged sword?

Innovation is commonly accepted as beneficial for consumers and the market, but pharmaceutical companies have also been accused of using innovation and patents as an anti-competitive sword against potential competitors. How can companies understand what is ‘good’ and ‘bad’ innovation?

Questions the panel are expected to discuss include:

  • Is the pharmaceutical industry in need of more regulation - or less?
  • Is product hopping to extend patent life a clever tactic, or deleterious for the market?
  • How are method of use patents seen by authorities and courts?
  • What has been and will be the impact of alleged sham patent litigation?
  • How should innovation be considered in merger review in the pharma sector?

13.15: Chairs’ closing remarks

Christine Meyer, NERA Economic Consulting, New York 
J Mark Gidley, White & Case, Washington DC

13.30: Close of conference

Event Map

Washington, DC